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 IgA nephropathy (IgAN) and Henoch –
 Sch ö nlein purpura (HSP) are both dis-
eases characterized by deposition of 
circulating IgA1-containing immune 
complexes (IgA-ICs). 1 Unlike IgAN, in 
which IgA-IC deposition occurs solely 
within the glomerulus, HSP is a small-ves-
sel systemic vasculitis characterized by 
IgA-IC deposition in aff ected blood ves-
sels. Up to 40 % of patients with HSP will 
develop a mesangial proliferative glomer-
ulonephritis, HSP nephritis (HSPN), 
which is usually indistinguishable from 
IgAN. Th ere is much indirect evidence to 
suggest a close relationship between IgAN 
and HSP. Monozygotic twins have been 
described, one of whom developed IgAN 
and the other HSP at the same time. HSP 
developing on a background of proven 
IgAN has been described in both adults 
and children. Many abnormalities of the 
IgA immune system, including changes in 
the profi le of circulating IgA1  O -glyco-
forms, have been described in both IgAN 
and HSP. Signifi cantly, an increase in the 
levels of poorly galactosylated IgA1  O -gly-
coforms appears to be specifi cally associ-
ated with development of nephritis in 
HSP. 2 Th e study by Kiryluk  et al. 3 (this 
issue) confi rms that children with IgAN 
and HSPN have raised levels of poorly 
galactosylated IgA1  O -glycoforms in their 
serum. Importantly, they also show that 
these children frequently have a parent 
with a similar serum IgA1  O -glycoform 
profi le, highlighting the importance of 
genetic factors in determining the consti-
tution of serum IgA1  O -glycoforms in 
IgAN and HSPN. 
 ARE CHANGES IN IgA1  O -GLYCOSYLATION 
ALONE SUFFICIENT TO CAUSE DISEASE? 
 As Kiryluk  et al. 3 discuss, an increase 
in the levels of poorly galactosylated 
IgA1  O -glycoforms appears insuffi  -
cient in itself to cause IgAN or HSPN, 
as fi rst-degree relatives with high se-
rum levels of poorly galactosylated IgA1 
 O -glycoforms exhibited no signs of 
either IgAN or HSPN. Th ese observations 
are similar to those reported in cohorts 
of white, Asian, and African-American 
families with IgAN. 4 – 6 Th ese new data 
add weight to the suggestion that a  ‘ sec-
ond hit ’ is required before high levels of 
poorly galactosylated IgA1 translate into 
overt disease. Current evidence would 
suggest that this second hit is the for-
mation of glycan-specifi c IgG (and IgA) 
antibodies that drive formation of large 
circulating immune complexes prone 
to deposition. Poorly galactosylated 
IgA1  O -glycoforms might act either as 
autoantigens driving the formation of 
glycan-specifi c antibodies in susceptible 
individuals, or as antigens for crossreac-
tive anti-microbial antibodies. 
 WHAT ARE THE GENETIC FACTORS 
CONTROLLING IgA1  O -GLYCOSYLATION 
IN IgAN AND HSPN? 
 Not surprisingly, signifi cant eff orts have 
been made to try and establish the ge-
netic basis for IgAN; however, little 
work has been undertaken in HSP. Four 
genome-wide scans (three in familial 
and one in sporadic IgAN) have identi-
fi ed susceptibility loci on chromosomes 
6q22, 6p, 4q26 – 31, 17q12 – 22, and 2q36. 
None of these loci correspond to genes 
directly involved in IgA1  O -glycosyla-
tion, and therefore the genes involved in 
determining the composition of serum 
IgA1  O -glycoforms remain unknown. 
A number of small case-control asso-
ciation studies have looked at single-
nucleotide polymorphisms in genes for 
specifi c glycosyltransferases involved 
in IgA1  O -glycosylation ( Figure 1 ). 
Polymorphisms in the  C1GALT1 and 
 ST6GALNAC2 genes, encoding core 1 
  1,3-galactosyltransferase (C1  3Gal-T) 
and   2,6-sialyltransferase, respectively, 
are associated with a genetic susceptibil-
ity to IgAN in a Chinese population. Ge-
nomic analyses in European and Chinese 
populations have identifi ed no COSMC 
(core 1   1-phosphate uridyltransferase 
(Gal-T)-specifi c molecular chaperone) 
gene variants in sporadic or familial 
IgAN. Cosmc is a molecular chaperone 
involved in the folding and stability of 
C1  3Gal-T. Without Cosmc, translated 
C1  3Gal-T is lost and there is defi ciency 
of galactose on glycoprotein acceptors. 
Th e single-nucleotide polymorphism in 
the promoter region of ST6GALNAC2 
that has been linked with development 
of IgAN has been shown  in vitro to 
signifi cantly reduce promoter activity 
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and   2,6-sialylation of IgA1 compared 
with the more common haplotype. Data 
from the United States would, however, 
suggest that reduced galactosylation of 
IgA1 in IgAN is due to enhanced   2,6-
sialyltransferase activity, with sialyla-
tion of  N -acetylgalactosamine (GalNAc) 
preventing the further addition of galac-
tose. It could be that these reported diff er-
ences in IgA1   2,6-sialylation refl ect dif-
ferent pathogenic processes operating in 
diff erent races; alternatively, the impact of 
these polymorphisms on the functional 
activity of   2,6-sialyltransferase may vary 
in specifi c B-cell subsets  in vivo . 
 Studies examining the expression of 
mRNA for the different glycosyltrans-
ferases have also been reported. One study 
showed reduced mRNA levels of Cosmc in 
peripheral blood B cells in IgAN, while 
C1  3Gal-T mRNA levels were unaltered. 
Furthermore, this reduction in Cosmc 
mRNA correlated with the level of poorly 
galactosylated IgA1 in the serum at the 
time of sampling. How these changes in 
Cosmc mRNA levels related to functional 
activity of C1  3Gal-T was not assessed. A 
separate study reported reduced sialylation 
of serum IgA1 and decreased expression 
of ST6GALNAC2 in peripheral blood B 
cells in Chinese patients. 
 DO FACTORS OTHER THAN THE 
GLYCOSYLTRANSFERASES DETERMINE 
IgA1  O -GLYCOSYLATION IN IgAN AND 
HSPN? 
 What is clear from the available evidence 
is that patients with IgAN can produce 
IgD and IgA1 that is highly galactosylat-
ed. It is also important to acknowledge 
that only a small fraction of serum IgA1 
is poorly galactosylated; therefore, only 
a small proportion of IgA1-committed 
plasma cells are synthesizing these gly-
coforms of IgA1. It is therefore unlikely 
that there is an overarching  ‘ defect ’ in 
immunoglobulin  O -glycosylation in 
IgAN or HSP. We believe that it is more 
likely that factors outside the immediate 
 O -glycosylation machinery of the plasma 
cell are responsible for the changes seen 
in the composition of serum IgA1  O -
glycoforms in IgAN and HSPN and that 
this is where the genetic origins of IgAN 
and HSPN are to be found. A number 




















 Figure 1  |  Potential pathways responsible for determining the composition of serum IgA1 
O-glycoforms in IgA nephropathy and Henoch – Sch ö nlein purpura nephritis. The initial event 
in  O -glycosylation of the IgA1 hinge region is the addition of  N -acetylgalactosamine (GalNAc) 
to threonine or serine residues, which is under the control of UDP- N -acetyl-  - D -galactosamine:
polypeptide  N -acetylgalactosaminyltransferase 2 (pp-GalNAc-T2). GalNAc may then be either 
sialylated in an   2,6-linkage or galactosylated via a   1,3-linkage. It has been proposed that 
sialylation of GalNAc prevents further extension of the core 1 structure with galactose, and 
that therefore the balance between the activity of   2,6-sialyltransferase and the activity of core 1 
  1,3-galactosyltransferase (C1  3Gal-T) determines the synthesis of poorly galactosylated IgA1 
 O -glycoforms. The function of C1  3Gal-T is dependent on the presence of a molecular chaperone, 
Cosmc.   2,3-Sialyltransferase catalyzes the terminal sialylation of galactosylated GalNAc. 
Polymorphisms within the genes encoding these  O -glycosyltransferases could result in production 
of poorly galactosylated IgA1; however, there is little convincing evidence to suggest this is the 
case in IgAN and HSPN. External factors, which are also likely to be subject to genetic variation, may 
influence glycosyltransferase activity and drive IgA1-committed plasma cells to synthesize poorly 
galactosylated IgA1. These include B-cell imprinting at the time of mucosal antigen encounter, 
cytokine expression within the local microenvironment, and Toll-like receptor activation by 
bacterial lipopolysaccharide (LPS) and bacterial DNA sequences with unmethylated cytosine –
 guanine dinucleotide (CpG) motifs. Alternatively, it is possible that plasma-cell glycosyltransferase 
activity is completely normal in IgAN and HSPN, but because of translocation of mucosally 
imprinted B cells to systemic sites due to faulty homing signals, these plasma cells release 
normal  ‘ mucosal-type ’ polymeric poorly galactosylated IgA1 directly into the circulation rather 
than into the submucosa for transport across the mucosal epithelium and into mucosal secretions. 
IL-4, interleukin-4; LBP, LPS binding protein. 
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modulate IgA synthesis and glycosyl-
transferase expression and could be sub-
ject to genetic variation ( Figure 1 ). Th ese 
include B-cell programming at the time 
of antigen encounter, cytokine expres-
sion within the local microenvironment, 
and Toll-like receptor (TLR) activation. 
 Mucosal imprinting of B cells and IgA1 
 O -glycosylation 
 Secretory IgA comprises a quite diff erent 
spectrum of  N - and  O -glycoforms than 
serum IgA, suggesting that mucosal 
IgA synthesis may at least in some way 
be associated with site-specifi c IgA1 
glyco sylation. Consistent with this obser-
vation, we have shown that IgA1  O -glyco-
forms with specifi city for mucosal antigens 
are poorly galactosylated compared with 
IgA1  O -glycoforms against systemic 
antigens, both in healthy subjects and in 
IgAN. 7 Th is suggests that during nor-
mal priming and maturation of mucosal 
B cells there is imprinting for a specifi c 
pattern of IgA1  O -glycosylation charac-
terized by poor galactosylation of the 
IgA1 hinge region. External mucosal 
factors driving this process might include 
the local cytokine milieu and co-ligation 
of Toll-like receptors. We have hypothe-
sized that the excessive amounts of poorly 
galactosylated IgA1  O -glycoforms in the 
circulation in IgAN result from mis-hom-
ing of normal mucosally primed plasma 
cells to systemic sites, with secretion of 
normal, but nephritogenic,  ‘ mucosal-type ’ 
IgA1 into the circulation. If this is the case, 
then genetic variation in the expression 
of B-cell homing receptors or endothelial 
addressins could underlie the increased 
levels of poorly galactosylated IgA1 char-
acteristic of IgAN and HSPN. 
 The cytokine milieu and IgA1  O -glyco sylation 
 Recent work using a surface IgA1-
positive human B lymphoma cell line 
has shown that the T-helper 2 cytokine 
interleukin-4 may play a key role in 
controlling  O -glycosylation of the IgA1 
hinge region. Interleukin-4 stimulation 
signifi cantly decreased the mRNA levels 
of both C1  3Gal-T and Cosmc. In paral-
lel, C1  3Gal-T activity was reduced and 
the synthesized IgA1  O -glycoforms were 
poorly galactosylated. 8 Studies in animal 
models of IgAN have similarly shown 
that IgA  N -glycosylation can be infl u-
enced by locally synthesized cytokines, 
in particular the T-helper 2 cytokines. 
 Toll-like receptors, mucosal pathogens, and 
IgA1  O -glycosylation 
 Toll-like receptors play key roles in 
innate immunity to microbial pathogens 
via recognition of a diverse range of 
pathogen-associated molecular patterns, 
such as bacterial lipopolysaccharide, 
RNAs, and DNAs. TLR-9 is expressed 
by B lymphocytes and binds bacte-
rial DNA sequences with unmethylated 
cytosine – guanine dinucleotide (CpG) 
motifs. Ligation of TLR-9 leads to poly-
clonal activation of B cells, class switch-
ing, and immunoglobulin production. 
IgA secretion by mucosal lamina pro-
pria and tonsillar B cells is increased 
aft er TLR-9 stimulation, implying that 
mucosal B cells can recognize patho-
gen-associated molecular patterns and 
secrete IgA in a T cell-independent 
manner. Nasal challenge with CpG oli-
godeoxynucleotides has been shown to 
increase serum IgA levels and accentu-
ate mesangial IgA deposition and renal 
injury in an IgAN-prone mouse model. 9 
At present there are no data on expression 
of TLR-9 in human IgAN or the eff ect of 
ligation on  O -glycosylation of IgA1; how-
ever, as TLR-9 is expressed on mucosal 
B cells, it would not be surprising if liga-
tion resulted in increased release of poorly 
galactosylated polymeric IgA1. TLR-4 is 
found principally on myeloid cells, but 
it is also expressed on mature B cells. TLR-4 
can bind a large variety of exogenous and 
endogenous agonists, including Gram-neg-
ative bacterial lipopolysaccharide and heat-
shock proteins of bacterial and host origin. 
Ligation of B-cell TLR-4 by bacterial lipopol-
ysaccharide induces methylation of the 
Cosmc gene, leading to reduced activity of 
C1  3Gal-T and reduced galactosylation of 
IgA1. 10 Whether B-cell TLR-4 expression is 
altered in IgAN is not known; however, 
these  in vitro data provide early evidence 
that specifi c mucosal pathogens might be 
able to infl uence the  O -glycosylation of mu-
cosal IgA1 antibodies. 
 WHERE DO WE GO NEXT? 
 Th e study of Kiryluk  et al. 3 reinforces 
the notion that changes in the profi le of 
serum IgA1  O -glycoforms are not enough 
in themselves to cause IgAN, or HSPN. An 
increase in serum levels of poorly galacto-
sylated IgA1 does, however, remain the 
most consistent fi nding in patients with 
IgAN and HSPN and is likely to be the 
trigger for the subsequent development 
of nephritogenic IgA immune complexes. 
Th ere is increasing evidence that genetic 
factors strongly infl uence the  O -glycosyla-
tion profi le of serum IgA1 in IgAN and 
HSPN; however, the genes responsible for 
this are at present unknown. An increased 
realization of the importance of extrinsic 
factors in control of IgA1  O -glycosylation 
means investigators will need to widen 
their net when searching for these genetic 
factors, as the primary abnormality could 
lie in biochemical pathways far distant 
from the glycosyltransferases. 
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